Liraglutide vs Tirzepatide: What the Research Shows
Liraglutide and Tirzepatide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Liraglutide if…
- you want an FDA-approved product: Saxenda (liraglutide) is labelled, with diet and activity, to reduce excess body weight and keep it off long term in adults with obesity or with overweight plus a comorbidity[13]
- you want a diabetes label for liraglutide: Victoza is indicated to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes[11]
Consider Tirzepatide if…
- you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[10]
- you want large randomized weight-loss data (the SURMOUNT program): Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo.[12]
Spec comparison
Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | Liraglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 agonist | GLP-1 / GIP dual agonist |
| Also called | Saxenda, Victoza | tirz, tirze, Mounjaro, Zepbound |
| FDA status | FDA approved (Saxenda, Victoza) | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | [half-life by route] | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | [n] | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses | [dose range] |
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
No direct trial, so read the two programmes side by side
The pivotal tirzepatide obesity trial enrolled adults with obesity and no diabetes and compared several dose levels with placebo over a long treatment period.[12]
At the top dose, tirzepatide's average weight change at the end of that trial was about a fifth of body weight, against a small change on placebo.[12]
The nearest liraglutide yardstick is the semaglutide head-to-head, where liraglutide at the Saxenda dose achieved a much smaller average loss than the weekly semaglutide arm.[14]
Tirzepatide was reported in the NEJM trial across three fixed-dose arms, whereas Saxenda's label has a single maintenance dose, so the dose-response story exists only for tirzepatide.[13]
Practical differences from the labels
The mechanisms differ: Zepbound's label describes a drug acting on both GIP and GLP-1 receptors, while liraglutide acts on GLP-1 alone.[10]
Zepbound has a second labelled use that Saxenda does not: moderate to severe obstructive sleep apnoea in adults with obesity.[10]
Dose escalation runs on different clocks: tirzepatide steps up in 2.5 mg increments after at least 4 weeks, while liraglutide climbs weekly to its target dose.[10]
Liraglutide is a daily injection with a half-life of 13 hours, and tirzepatide is weekly.[13]
Tirzepatide's own label gives the half-life that explains the weekly schedule, and it affects how long side effects may last after stopping.[10]
Common questions
Is Zepbound better than Saxenda?
No trial pits them directly. Separate trials show Zepbound's top dose with about a fifth of body weight lost, versus a much smaller loss on liraglutide in the semaglutide head-to-head.[12]
Can you switch from Saxenda to Zepbound?
The labels describe starting at the lowest dose and stepping up, and nothing in them gives a switching schedule; ask the prescriber.[10]
Victoza vs Zepbound: what is the difference?
Victoza is liraglutide for type 2 diabetes and is injected daily; Zepbound is tirzepatide for weight and sleep apnoea and is injected weekly.[11]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 7Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 8Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 9PubMed search: (liraglutide[tiab] OR Victoza[tiab] OR Saxenda[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11VICTOZA prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 12Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 13SAXENDA prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 14Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA · 2022PMID 35015037Accessed 2 Oct 2026
Found an error? Report a correction.